Unity Biotechnology, Inc.

285 East Grand Ave.

South San Francisco, CA 94080

December 7, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

Securities and Exchange Commission

Washington, D.C. 20549

Attention: Joshua Gorsky

Re: Unity Biotechnology, Inc.

Registration Statement on Form S-3

Filed on December 6, 2023

File No. 333-275924 (the “Registration Statement”)

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Unity Biotechnology, Inc. (the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on December 8, 2023, or as soon thereafter as practicable.

Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Alla Digilova, Esq. at (212) 659-4993.

Very truly yours,
UNITY BIOTECHNOLOGY, INC.
By:	/s/ Anirvan Ghosh
	Anirvan Ghosh
	Chief Executive Officer

cc: Alla Digilova, Esq., Haynes and Boone, LLP